Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Translating BTK Inhibitor Data into Clinical Decision-Making

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

Dr Opat on the Accessibility of Sonrotoclax Plus Zanubrutinib in R/R CLL/SLL

July 31st 2024

Stephen Opat, MBBS, discusses the accessibility of sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

July 30th 2024

The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.

Navigating 2L Treatment Options in CLL

July 30th 2024

Experts on chronic lymphocytic leukemia discuss treatment practices for patients with relapsed/refractory CLL and provide insights on the role for venetoclax in patients who previously received BTK inhibitors.

Dr Opat on Sonrotoclax With Zanubrutinib in Relapsed/Refractory CLL and SLL

July 29th 2024

Stephen Opat, MBBS, discusses sonrotoclax plus zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Fixed-Duration Acalabrutinib/Venetoclax Yields PFS Benefit vs SOC in Frontline CLL

July 29th 2024

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab elicited favorable PFS outcomes in previously untreated chronic lymphocytic leukemia.

BTKi Intolerance in Real-world Practice & Management Strategy

July 29th 2024

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

How Experts View MAIC Data That was Presented at EHA 2024

July 29th 2024

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

July 25th 2024

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

July 25th 2024

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

Patient with R/R CLL Treated with 2L Venetoclax Therapy

July 23rd 2024

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Expert Insights for Long-Term Treatment Planning in CLL

July 23rd 2024

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

Dr Fürstenau on the Rationale for the GAIA/CLL13 Trial in Previously Untreated CLL

July 23rd 2024

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL

July 22nd 2024

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Navigating Treatment Approaches for R/R CLL

July 22nd 2024

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

July 22nd 2024

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

July 17th 2024

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

July 16th 2024

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.